Table 1.

Next-generation antitumor antibodies optimized for Fc-mediated effector function

NameTargetIndicationCompanyFc optimization strategy
MGA271B7-H3B7-H3+ carcinomas (solid tumors)MacroGenicsFc domain point mutants
MGAH22 (margetuximab)HER2Breast cancerMacrogenicsFc domain point mutants
XmAb-2513CD30Hodgkin lymphomaXencorFc domain point mutants
XmAb-5574CD19Leukemia/lymphoma (CLL)XencorFc domain point mutants
AME-133v (ocaratuzumab, LY2469298)CD20Leukemia/lymphoma (NHL: CLL, FL)Mentrik/Eli LillyFc domain point mutants
Obinutuzumab (GA101)CD20Leukemia/lymphoma (NHL: CLL, FL)RocheAfucosylated Fc domain
GA201 (RG7160)EGFRVarious carcinomasRocheAfucosylated Fc domain
MEDI-551CD19Leukemia/lymphoma (CLL)MedimmuneAfucosylated Fc domain
KW2871GD3 gangliosideMelanomaLife Science PharmaceuticalsAfucosylated Fc domain
ARGX-110CD70CD70+ tumorsArgen-xAfucosylated Fc domain
ARGX-111c-MetcMet+ tumorsArgen-xAfucosylated Fc domain
QuilizumabM1 of IgEIgE+ B cellsGenentechAfucosylated Fc domain
OBT357 (MEN1112)Bst1 (CD157)Acute myeloid leukemiaMenarini Group/Oxford BioTherapeuticsAfucosylated Fc domain
BIW-8692Ganglioside GM2Lung cancerKyowa Hakko KirinAfucosylated Fc domain
Mogamulizumab (KW-0761)CCR4Peripheral and cutaneous T-cell lymphomasKyowa Hakko KirinAfucosylated Fc domain
CetuGEXEGFRVarious carcinomasGlycotopeAfucosylated Fc domain
Pankomab-GEXMUC1Ovarian cancerGlycotopeAfucosylated Fc domain
Tras-GEXHER2Breast cancerGlycotopeAfucosylated Fc domain
KB004EphA3Hematologic and solid tumorsKaloBios PharaceuticalsAfucosylated Fc domain

Abbreviations: CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; NHL, non-Hodgkin lymphoma.